Beijing Suncadia

Beijing Suncadia Biopharmaceuticals is a premier research and development subsidiary of Jiangsu Hengrui Pharmaceuticals, one of China's largest and most innovative pharmaceutical enterprises. Based in Beijing, the company serves as a critical hub for the discovery, clinical development, and regulatory submission of novel therapeutics, with a heavy focus on oncology, metabolic diseases, and autoimmune disorders. Suncadia manages a robust pipeline that includes high-profile assets such as the PD-1 inhibitor camrelizumab and the HER2 inhibitor pyrotinib. By integrating advanced drug discovery platforms with extensive clinical trial management, the company has successfully brought multiple innovative drugs to the Chinese market. As a core pillar of Hengrui's global expansion strategy, Beijing Suncadia continues to advance a diverse portfolio of small molecules, monoclonal antibodies, and antibody-drug conjugates.